News

Filter

Current filters:

United Therapeutics

United Thera scores over Sandoz in Remodulin patent case

United Thera scores over Sandoz in Remodulin patent case

31-08-2014

US biotech company United Therapeutics’ shares leapt 28.5% to $117.83 on Friday, after the company…

GenericsLegalNovartisPatentsRemodulinRespiratory and PulmonarySandozUnited TherapeuticsUSA

Surprise US FDA approval for United Thera’s Orenitram ER for PAH

Surprise US FDA approval for United Thera’s Orenitram ER for PAH

23-12-2013

In what was seen by some observers as unexpected, the US Food and Drug Administration has approved United…

BiotechnologyNorth AmericaOrenitramRegulationRespiratory and PulmonaryTreprostinilUnited Therapeutics

United Therapeutics subpoenaed over drug marketing practices

09-12-2013

US drugmaker United Therapeutics says it has received a subpoena from the Office of the Inspector General…

AdcircaLegalMarkets & MarketingNorth AmericaPharmaceuticalRemodulinTyvasoUnited Therapeutics

United Therapeutics sues Sandoz over Remodulin patent infringement

16-03-2012

United Therapeutics (Nasdaq: UTHR) says that it has filed a law suit in the US District Court for the…

Cardio-vascularGenericsLegalNorth AmericaNovartisPatentsPharmaceuticalRemodulinSandozUnited Therapeutics

Sandoz challenges United Thera’s Remodulin patents

06-02-2012

US drugmaker United Therapeutics (Nasdaq: UTHR) says that it has received a Paragraph IV Certification…

GenericsNorth AmericaNovartisPatentsPharmaceuticalRegulationRemodulinRespiratory and PulmonarySandozUnited Therapeutics

United Thera’s oral PAH drug treprostinil fails in Ph III study

26-08-2011

US biotech firm United Therapeutics (Nasdaq: UTHR) says that preliminary results from its FREEDOM-C(2)…

BiotechnologyRegulationResearchRespiratory and PulmonaryTreprostinilUnited Therapeutics

Back to top